BioCardia’s CardiALLO Trial Advances After Safety Review

The latest update is out from BioCardia ( (BCDA) ).

On April 15, 2025, BioCardia announced that the independent Data Safety Monitoring Board recommended the continuation of the CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial, following a positive review of the 30-day safety data. The trial, which showed no major adverse cardiac events or immune reactions, is set to progress with the enrollment of 39 participants in the United States. This development is significant for BioCardia’s MSC platform, potentially aiding discussions around funding and partnerships, and could lead to future pivotal trials and approvals in the USA and Japan.

Spark’s Take on BCDA Stock

According to Spark, TipRanks’ AI Analyst, BCDA is a Underperform.

BioCardia faces significant financial challenges, with ongoing losses and high volatility in revenue growth. While technical indicators suggest a potential rebound, the company’s valuation remains unattractive due to negative earnings. Positive trial results and financial improvements from the earnings call provide some optimism, but the failure to meet primary endpoints and unexpected market reactions highlight ongoing risks.

To see Spark’s full report on BCDA stock, click here.

More about BioCardia

BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company develops biotherapeutic platforms such as CardiAMP® autologous and CardiALLO™ allogeneic cell therapies, supported by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms.

YTD Price Performance: -12.39%

Average Trading Volume: 66,767

Technical Sentiment Signal: Buy

Current Market Cap: $9.27M

Learn more about BCDA stock on TipRanks’ Stock Analysis page.